Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR (2019) Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol 15:405–417. https://doi.org/10.1038/s41582-019-0220-2

Article  PubMed  PubMed Central  Google Scholar 

Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol 24:v1–v95. https://doi.org/10.1093/neuonc/noac202

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812. https://doi.org/10.1126/science.1164382

Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474. https://doi.org/10.1007/s00401-009-0561-9

Article  PubMed  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Franceschi E, Tosoni A, Bartolini S, Minichillo S, Mura A, Asioli S, Bartolini D, Gardiman M, Gessi M, Ghimenton C, Giangaspero F, Lanza G, Marucci G, Novello M, Silini EM, Zunarelli E, Paccapelo A, Brandes AA (2020) Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. Eur J Cancer 137:10–17. https://doi.org/10.1016/j.ejca.2020.06.018

Article  CAS  PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996.https://doi.org/10.1056/NEJMoa043330

Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ (2020) Glioblastoma in adults: a society for neuro-oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22:1073–1113. https://doi.org/10.1093/neuonc/noaa106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN (2022) World health organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review. JAMA Oncol 8:1493–1501. https://doi.org/10.1001/jamaoncol.2022.2844

Article  PubMed  Google Scholar 

Bush NA, Butowski N (2017) The effect of molecular diagnostics on the treatment of glioma. Curr Oncol Rep 19:26. https://doi.org/10.1007/s11912-017-0585-6

Article  CAS  PubMed  Google Scholar 

Diamandis P, Aldape KD (2017) Insights from molecular profiling of adult glioma. J Clin Oncol 35:2386–2393. https://doi.org/10.1200/JCO.2017.73.9516

Article  CAS  PubMed  Google Scholar 

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331

Article  CAS  PubMed  Google Scholar 

Marquart J, Chen EY, Prasad V (2018) Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol 4:1093–1098. https://doi.org/10.1001/jamaoncol.2018.1660

Article  PubMed  PubMed Central  Google Scholar 

Haslam A, Kim MS, Prasad V (2021) Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006–2020. Ann Oncol 32:926–932. https://doi.org/10.1016/j.annonc.2021.04.003

Article  CAS  PubMed  Google Scholar 

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM (2018) BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 36:3477–3484. https://doi.org/10.1200/JCO.2018.78.9990

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF, Wen PY (2021) Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I Trial. Clin Cancer Res 27:4491–4499. https://doi.org/10.1158/1078-0432.CCR-21-0611

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doz F, van Tilburg CM, Geoerger B, Hojgaard M, Ora I, Boni V, Capra M, Chisholm J, Chung HC, DuBois SG, Gallego-Melcon S, Gerber NU, Goto H, Grilley-Olson JE, Hansford JR, Hong DS, Italiano A, Kang HJ, Nysom K, Thorwarth A, Stefanowicz J, Tahara M, Ziegler DS, Gavrilovic IT, Norenberg R, Dima L, De La Cuesta E, Laetsch TW, Drilon A, Perreault S (2022) Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol 24:997–1007. https://doi.org/10.1093/neuonc/noab274

Article  CAS  PubMed  Google Scholar 

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739. https://doi.org/10.1056/NEJMoa1714448

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V (2022) Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 23:53–64. https://doi.org/10.1016/S1470-2045(21)00578-7

Article  CAS  PubMed  Google Scholar 

Kukurba KR, Montgomery SB (2015) RNA sequencing and analysis. Cold Spring Harb Protoc 2015:951–969. https://doi.org/10.1101/pdb.top084970

Article  PubMed  PubMed Central  Google Scholar 

Piskol R, Ramaswami G, Li JB (2013) Reliable identification of genomic variants from RNA-seq data. Am J Hum Genet 93:641–651. https://doi.org/10.1016/j.ajhg.2013.08.008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goya R, Sun MG, Morin RD, Leung G, Ha G, Wiegand KC, Senz J, Crisan A, Marra MA, Hirst M, Huntsman D, Murphy KP, Aparicio S, Shah SP (2010) SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 26:730–736. https://doi.org/10.1093/bioinformatics/btq040

Article  CAS  PubMed  PubMed Central  Google Scholar 

Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E (2017) The functional impact of alternative splicing in cancer. Cell Rep 20:2215–2226. https://doi.org/10.1016/j.celrep.2017.08.012

Article  CAS  PubMed  Google Scholar 

Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, Luo FR, Soria JC, Tabernero J, Eoli M, Paterra R, Yip S, Petrecca K, Chan JA, Finocchiaro G, Lasorella A, Sanson M, Iavarone A (2015) Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res 21:3307–3317. https://doi.org/10.1158/1078-0432.CCR-14-2199

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song J, Singh M (2009) How and when should interactome-derived clusters be used to predict functional modules and protein function? Bioinformatics 25:3143–3150. https://doi.org/10.1093/bioinformatics/btp551

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kohsaka S, Tatsuno K, Ueno T, Nagano M, Shinozaki-Ushiku A, Ushiku T, Takai D, Ikegami M, Kobayashi H, Kage H, Ando M, Hata K, Ueda H, Yamamoto S, Kojima S, Oseto K, Akaike K, Suehara Y, Hayashi T, Saito T, Takahashi F, Takahashi K, Takamochi K, Suzuki K, Nagayama S, Oda Y, Mimori K, Ishihara S, Yatomi Y, Nagase T, Nakajima J, Tanaka S, Fukayama M, Oda K, Nangaku M, Miyazono K, Miyagawa K, Aburatani H, Mano H (2019) Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. Cancer Sci 110:1464–1479. https://doi.org/10.1111/cas.13968

Article  CAS  PubMed  PubMed Central